Home / Health / New Amylin-Based Injection Promises Effective Weight Loss with Reduced Muscle Loss
New Amylin-Based Injection Promises Effective Weight Loss with Reduced Muscle Loss
10 Nov
Summary
- Eloralintide, a new weight loss injection, matches Mounjaro's effectiveness
- Patients may experience less lean muscle mass loss compared to Ozempic and Wegovy
- Injection also improves blood pressure, blood sugar, and inflammation markers
According to a recent study, a new weight loss injection called Eloralintide, produced by Eli Lilly and Company, may offer a promising alternative to popular GLP-1 drugs like Ozempic and Wegovy. The once-weekly injection, an amylin analog, has been shown to be as effective as Mounjaro in helping patients lose up to 20.1% of their body weight.
Notably, Eloralintide may lead to a lower loss of lean muscle mass compared to other weight loss drugs. This is a significant advantage, as rapid weight loss can often result in the loss of both fat and muscle. The new injection has also demonstrated improvements in patients' blood pressure, blood sugar, and markers of inflammation.
While some adverse events, such as mild to moderate gastrointestinal symptoms and fatigue, have been reported, the company plans to begin enrolling Phase 3 clinical studies of Eloralintide next month. Experts believe that having a variety of weight loss therapies with different mechanisms of action is crucial to address the complex needs of each patient.
